i3 Health Receives NCPD Premier Award From the American Nurses Credentialing Center NCPD Accreditation Program

i3 Health is honored to be recognized as a 2022 recipient of the Nursing Continuing Professional Development (NCPD) Premier Award presented by the American Nurses Credentialing Center (ANCC) NCPD Accreditation Program. Awarded annually, the NCPD Premier Award is presented to accredited providers that excel in developing high-quality NCPD-accredited educational activities. Recipients of this prestigious award are exemplary organizations that serve as role models in the field of nursing education....

Continue reading

Staying Up To Date On Treatment of Myelofibrosis With John Mascarenhas, MD

Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians.  

Continue reading

Bridging Knowledge Gaps for Treatment of Immune Thrombocytopenia

i3 Health has provided an educational activity that has challenged knowledge gaps experienced by nursing staff regarding updated treatment options and optimal patient care for immune thrombocytopenia (ITP). ITP is an autoimmune platelet disorder in which the blood does not clot normally as a result of a low platelet count, causing bruising and bleeding. Research has shown that the burden of ITP is significant; in a survey of more than 1,300 patients from 13 different countries, 36% reported a hi...

Continue reading

Closing Nurses’ Knowledge Gaps Regarding Treatment of Castration-Resistant Prostate Cancer

An educational live and enduring activity provided by i3 Health has demonstrated knowledge gains and learning outcomes for nurses treating patients with castration-resistant prostate cancer (CRPC). Prostate cancer is the most common tumor type in men, affecting one in eight men in the United States. The estimate for 2022 is expecting 268,490 new cases of prostate cancer, with 34,500 of those cases resulting in death. The typical treatment for progressive prostate disease is androgen deprivation ...

Continue reading

Understanding the Current Landscape of Chemotherapy-Induced Neutropenia With Maura Abbott, NP, MSN, PhD

Chemotherapy-induced neutropenia (CIN) is a common and potentially life-threatening consequence of chemotherapy, as it may lead to serious infections for patients with cancer. These infections result in hospital stays, increased morbidity and mortality, and considerable financial burden. In this interview, Dr. Maura Abbott explains the importance of managing and educating patients about CIN.  

Continue reading

Understanding the Current Landscape of Chemotherapy-Induced Neutropenia With Maura Abbott, NP, MSN, PhD

Chemotherapy-induced neutropenia (CIN) is a common and potentially life-threatening consequence of chemotherapy, as it may lead to serious infections for patients with cancer. These infections result in hospital stays, increased morbidity and mortality, and considerable financial burden. In this interview, Dr. Maura Abbott explains the importance of managing and educating patients about CIN.  

Continue reading

i3 Health Presents Oncology Nursing Showdown: Non-Hodgkin Lymphoma Edition at Oncology Nursing Society Congress

i3 Health's study focusing on the effectiveness of a nursing continuing professional development (NCPD)–approved activity to improve clinicians' knowledge of the individualized treatment of patients with non-Hodgkin lymphoma (NHL) has been published as a 47th Annual Oncology Nursing Society (ONS) Congress online abstract. The abstract, authored by Elizabeth Heller, PhD; Keira Smith, BA; Kristin Wright, PharmD; and Sarah Williams, MAT, of i3 Health, and Maria Badillo, MSN, RN, OCN®, CCRP, Researc...

Continue reading

You’re Invited! Special Event: Diagnosis and Evidence-Based Management of T-Cell Lymphoma

i3 Health would like to cordially invite you to our upcoming event, Diagnosis and Evidence-Based Management of T-Cell Lymphoma, a live CME/NCPD-approved webinar. Due to high demand, we are pleased to offer two dates and times for this expert-led discussion: Monday, June 13, 2022, at 3:00 PM EDT, and Friday, June 17, 2022, at 12:00 PM EDT. T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States. The clinical and patho...

Continue reading

Oncology Showdown Activity Tackles Proficiency in Treatment of Advanced Non-Hodgkin Lymphoma

An educational live and enduring activity provided by i3 Health has demonstrated significant learning outcomes for treatment of patients with advanced non-Hodgkin lymphoma (NHL). The live activity, which was presented virtually at the 4th Annual GLAONS Oncology Care Summit, used a competitive, team-based "game show" format to explore the latest strategies and expert perspectives in treatment of patients with advanced NHL, including subtypes of follicular lymphoma (FL) and chronic lymphocytic leu...

Continue reading

Managing Treatment-Related Adverse Effects of Multiple Myeloma: Beth Faiman, PhD, MSN, APN-BC, AOCN®, FAAN

Multiple myeloma is a cancer of the bone marrow plasma cells that causes the overproduction of monoclonal immunoglobulins, which can lead to organ damage. In this excerpt of the transcript from her nursing continuing professional development (NCPD)-approved activity, Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care, Beth Faiman, PhD, MSN, APN-BC, AOCN®, FAAN, a nurse practitioner at the Cleveland Clinic Taussig Cancer Institute, discusses strateg...

Continue reading

Addressing Gaps in Knowledge of the Optimal Approach to Managing Myelofibrosis

Myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocytopenia, affect approximately 13,000, 134,000, and 148,000 individuals in the United States, respectively. Due to difficulties in identifying the disease, low disease prevalence, a complicated symptom profile, differences in patient and provider perspectives regarding symptom burden and treatment goals, and a lack of effective and tolerable therapies, there is confusion over the optimal approach to t...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.